Table 2.
Baseline characteristics prior treatment.
| Patients receiving vernakalant solely (n = 167) | Patients receiving vernakalant and ecv (n = 63) | P-value | |
|---|---|---|---|
| Vital signs | |||
| Systolic blood pressure in mmHg, median (IQR) | 128 (119–137) | 130 (120–140) | 0,927 |
| Heart rate, median (IQR) | 124 (110–140) | 120 (102–140) | 0,481 |
| NYHA stage >1, n (%) | 17 (10,2) | 13 (20,6) | 0,728 |
| NT-proBNP, median (IQR) | 445 (117–1194,25) | 527 (176,5–1173) | 0,491 |
| Echocardiographic assessment | |||
| Normal left ventricular function (>55%), n (%) | 153 (91,6) | 52 (82,5) | 0,654 |
| Impaired left ventricular function (<55%), n (%) | 12 (7,2) | 13 (20,6) | 0,651 |
| Normal atrial size, n (%) | 91 (54,5) | 36 (57,1) | 0,232 |
| Atrial enlargement, n (%) | 76 (45,5) | 27 (42,9) | 0,200 |
| Classification of prior AF episodes and duration of current AF episode | |||
| No prior episode of atrial fibrillation, n (%) | 49 (29,3) | 11 (17,5) | 0,753 |
| Paroxysmal atrial fibrillation, n (%) | 21 (12,6) | 4 (6,3) | 0,648 |
| Persistent atrial fibrillation, n (%) | 96 (57,5) | 49 (77,8) | 0,723 |
| Duration of current episode in hours, median (IQR) | 5,5 (3−11) | 6 (3–14) | 0,500 |
Unless otherwise indicated, data are numbers (percentages); ecv = electrical cardioverison; IQR = interquartile range; n = number; NYHA = New York Heart Association; NT-proBNP = N-terminal pro b-type natriuretic peptide.